Affimed N.V. (AFMD) Stock Price, Quote & News

Latest News on AFMD

$Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)$

Dec 9, 2024, 1:30 PM EST - 5 weeks ago

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Dec 9, 2024, 6:30 AM EST - 5 weeks ago

Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

$Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients$

Dec 8, 2024, 12:00 PM EST - 5 weeks ago

Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients

Dec 5, 2024, 6:30 AM EST - 6 weeks ago

Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)

Nov 14, 2024, 2:32 PM EST - 2 months ago

Affimed N.V. (AFMD) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 6:30 AM EST - 2 months ago

Affimed Reports Third Quarter 2024 Financial Results & Business Update

Nov 6, 2024, 6:30 AM EST - 2 months ago

Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024

Sep 10, 2024, 6:30 AM EDT - 4 months ago

Affimed to Present at the Cantor Global Healthcare Conference 2024

Sep 5, 2024, 11:17 AM EDT - 4 months ago

Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript

Sep 5, 2024, 6:30 AM EDT - 4 months ago

Affimed Reports Second Quarter 2024 Financial Results & Business Update

Sep 4, 2024, 4:40 PM EDT - 4 months ago

Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts

Sep 3, 2024, 7:45 AM EDT - 4 months ago

Affimed Appoints Shawn M. Leland as Chief Executive Officer

Aug 29, 2024, 6:30 AM EDT - 5 months ago

Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024

Jun 12, 2024, 10:48 AM EDT - 7 months ago

Affimed N.V. (AFMD) Q1 2024 Earnings Call Transcript

Jun 12, 2024, 6:30 AM EDT - 7 months ago

Affimed Reports First Quarter 2024 Financial Results & Business Update

Jun 11, 2024, 8:37 AM EDT - 7 months ago

Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better

Jun 5, 2024, 6:30 AM EDT - 8 months ago

Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024

Jun 1, 2024, 1:02 PM EDT - 8 months ago

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort

May 29, 2024, 6:30 AM EDT - 8 months ago

Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer

May 28, 2024, 6:30 AM EDT - 8 months ago

Affimed Announces Annual General Meeting of Shareholders

May 23, 2024, 5:05 PM EDT - 8 months ago

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024

May 14, 2024, 10:05 AM EDT - 8 months ago

Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress

Apr 24, 2024, 4:05 AM EDT - 9 months ago

Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology

Mar 28, 2024, 12:04 PM EDT - 10 months ago

Affimed N.V. (AFMD) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 6:30 AM EDT - 10 months ago

Affimed Reports 2023 Financial Results and Operational Progress

Mar 21, 2024, 6:30 AM EDT - 10 months ago

Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024

Mar 6, 2024, 6:30 AM EST - 11 months ago

Affimed Announces 1-for-10 Reverse Stock Split

Jan 8, 2024, 4:05 PM EST - 1 year ago

Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer

Jan 8, 2024, 8:00 AM EST - 1 year ago

Affimed Announces Leadership Change and Organizational Restructuring

Jan 3, 2024, 6:30 AM EST - 1 year ago

Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck

Dec 11, 2023, 6:02 AM EST - 1 year ago

Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients

$Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)$

Dec 11, 2023, 6:00 AM EST - 1 year ago

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24

Dec 4, 2023, 6:30 AM EST - 1 year ago

Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Nov 2, 2023, 9:05 AM EDT - 1 year ago

Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

Nov 1, 2023, 6:30 AM EDT - 1 year ago

Affimed to Participate in Upcoming Investor Conferences

Oct 4, 2023, 6:30 AM EDT - 1 year ago

Affimed Announces Listing Transfer to Nasdaq Capital Markets

Sep 27, 2023, 9:05 AM EDT - 1 year ago

Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Sep 21, 2023, 6:30 AM EDT - 1 year ago

Affimed to Present at the Cantor Global Healthcare Conference 2023

$Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma$

Sep 12, 2023, 6:30 AM EDT - 1 year ago

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

Sep 7, 2023, 6:30 AM EDT - 1 year ago

Affimed to Present at the H.C. Wainwright Annual Global Investment Conference

Aug 22, 2023, 5:00 AM EDT - 1 year ago

Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

Affimed N.V. (AFMD) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 11:57 AM EDT - 1 year ago

Market Cap	17.39M
Revenue (ttm)	8.96M
Net Income (ttm)	-114.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,279.69%
Debt to Equity Ratio	0.47

Volume	347,500
Avg Vol	375,034
Day's Range	N/A - N/A
Shares Out	16.10M
Stochastic %K	32%
Beta	2.17
Analysts	Strong Sell
Price Target	$13.60